Product Description
Olanzapine is used to treat the symptoms of schizophrenia (a mental illness that causes disturbed or unusual thinking, loss of interest in life, and strong or inappropriate emotions) in adults and teenagers 13 years of age and older. It is also used to treat bipolar disorder (manic depressive disorder; a disease that causes episodes of depression, episodes of mania, and other abnormal moods) in adults and teenagers 13 years of age and older. Olanzapine is in a class of medications called atypical antipsychotics. It works by changing the activity of certain natural substances in the brain. (Sourced from: https://medlineplus.gov/druginfo/meds/a601213.html)
Mechanisms of Action: H1 Antagonist,D2 Antagonist,5-HT3 Antagonist,5-HT2 Antagonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Approved
Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | China | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam
Approved Indications: Hypotension | Hypotension, Orthostatic | Bipolar Disorder | Depressive Disorder | Depressive Disorder, Treatment-Resistant | Schizophrenia | Dyslipidemia | Weight Gain
Known Adverse Events: Bradycardia | Tachycardia | Hypotension | Hypotension, Orthostatic | Postural Orthostatic Tachycardia Syndrome | Ischemic Stroke | Hyperprolactinemia | Neuroleptic Malignant Syndrome | Seizures | Stroke | Tardive Dyskinesia | Bipolar Disorder | Depressive Disorder | Suicidality | Amnesia | Dementia | Dementia, Vascular | Abdominal Pain | Back Pain | Coma | Dizziness | Headache | Labor Pain | Low Back Pain | Pain Unspecified | Paresthesia | Syncope | Tremor | Vision, Low | Schizophrenia | Anticholinergic Syndrome | Ileus | Agranulocytosis | Eosinophilia | Leukopenia | Neutropenia | Acidosis | Dyslipidemia | General Diabetes | Hyperglycemia | Asthenia | Constipation | Weight Gain
Company: Eli Lilly
Company Location: INDIANAPOLIS IN 46285
Company CEO: David A. Ricks
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: China, Croatia, Jordan, United States
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Depressive Disorder, Treatment-Resistant|Psychomotor Agitation|Schizophrenia
Phase 2: Central Nervous System Cancer|Motion Sickness|Pregnancy Outcomes
Phase 1: Acute Pain|Affective Disorders, Psychotic|Bipolar Disorder|Healthy Volunteers|Psychotic Disorders
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| QLG1130-301 | P3 |
Not yet recruiting |
Schizophrenia |
2026-04-01 |
|
| TV44749-BA-10196 | P1 |
Recruiting |
Schizophrenia |
2025-04-18 |
|
| TV44749-NPC-10205 | P1 |
Active, not recruiting |
Affective Disorders, Psychotic|Psychotic Disorders|Schizophrenia |
2024-12-11 |
|
| QLG2072-301 | P3 |
Not yet recruiting |
Psychomotor Agitation |
2024-05-07 |
90% |